Document is current
Any future updates will be listed below
-
Authors
,
Laurain, Anne http://orcid.org/0000-0002-9806-7953
Metivier, Sophie
Haour, Georges
Larrey, Dominique
Dorival, Céline
Hezode, Christophe
Zoulim, Fabien
Marcellin, Patrick
Bourliere, Marc
Zarski, Jean-Pierre
Thabut, Dominique
Alric, Laurent
Ganne-Carrie, Nathalie
Cales, Paul
Bronowicki, Jean-Pierre
Riachi, Ghassan
Geist, Claire
Causse, Xavier
Abergel, Armand
Chazouilleres, Olivier
Mathurin, Philippe
Guyader, Dominique
Samuel, Didier
Tran, Albert
Loustaud-Ratti, Véronique
Petrov-Sanchez, Ventzislava
Diallo, Alpha
Luzivika-Nzinga, Clovis
Fontaine, Hélène
Carrat, Fabrice
Pol, Stanislas
-
Funding
Funding for this research was provided by:
ANRS
DGS
MSD
Janssen Pharmaceuticals
Gilead Sciences
AbbVie
Bristol-Myers Squibb Foundation
Roche
- License Information
-
More Information
Article History
Received: 22 May 2018
Accepted: 19 March 2019
First Online: 2 April 2019
Ethics approval and consent to participate
: Written informed consent was obtained from each patient before enrolment. The protocol was performed in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the “CPP Ile de France 3” Ethics Committee (Paris, France) and the French Regulatory Authority (ANSM).
: not applicable.
: The ANRS CO22 HEPATHER cohort is sponsored and funded by Inserm-ANRS and conducted in collaboration with Association Française pour l’étude du Foie (AFEF). The cohort received supports from ANR (Agence Nationale de la Recherche), DGS (Direction Générale de la Santé) and MSD, Janssen, Gilead, Abbvie, BMS, Roche. The public/private partnership is built in total transparency through a specific contract. The pharmaceutical companies are not involved in the scientific decisions.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
